Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 367 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Papilloma Virus Infection Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

NCT06624839
View directory record Official record
Conditions
Human Papilloma Virus, Anal Dysplasia, HIV
Interventions
Human papillomavirus (HPV) vaccine, 9-valent
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

NCT06297187
View directory record Official record
Conditions
Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Interventions
CUSA (Cavitronic Ultrasonic Surgical Aspirator)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 20, 2026, 7:09 PM EDT
Terminated Phase 2 Interventional Results available

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

NCT04015336
View directory record Official record
Conditions
Papillomavirus Infections, Oropharyngeal Neoplasms
Interventions
E7 T-Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 20, 2026, 7:09 PM EDT
Active, not recruiting No phase listed Observational

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

NCT04965792
View directory record Official record
Conditions
HPV, Oropharyngeal Squamous Cell Carcinoma
Interventions
Screening
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

NCT03100045
View directory record Official record
Conditions
HPV-Related Anal Intraepithelial Neoplasia, AIN2/3, Artesunate, Alternative Treatment, Anal Dysplasia, Precancerous Conditions, Human Papilloma Virus
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

High-Risk HPV Infections in Women Aged 25 to 65

NCT00461877
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jul 20, 2026, 7:09 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205
View directory record Official record
Conditions
Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Interventions
Teal Wand Self-Collection Device Group
Device
Lead sponsor
Teal Health, Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples

NCT04423679
View directory record Official record
Conditions
Human Papilloma Virus, Cervical Cancer, CIN 2/3
Interventions
Evalyn Brush
Device
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 69 Years · Female only
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 20, 2026, 7:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

NCT05672927
View directory record Official record
Conditions
Immunization, HPV Infection, Human Papillomavirus
Interventions
9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
27 Years to 45 Years · Female only
Enrollment
618 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay, FDA-Approved HPV DNA Test
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
12,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Results available

HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer

NCT04580446
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
Interventions
Hypofractionated intensity modulated radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

NCT00435214
View directory record Official record
Conditions
Cervical Neoplasia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years to 100 Years · Female only
Enrollment
131,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 20, 2026, 7:09 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Standing Orders Optimization

NCT05742386
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Communication training, Communication training enhanced with standing orders optimization
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 20, 2026, 7:09 PM EDT
Terminated Phase 2 Interventional

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

NCT03158974
View directory record Official record
Conditions
Condylomata Acuminata
Interventions
East Indian Sandalwood Oil Cream
Drug
Lead sponsor
ViroXis Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 20, 2026, 7:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

NCT01084824
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid nitrogen and cantharidin, Liquid nitrogen and topical placebo
Drug
Lead sponsor
North Idaho Dermatology
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Jul 20, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

NCT02048020
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions
paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

NCT00767897
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis
Interventions
Human Papillomavirus Vaccine
Drug
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 20, 2026, 7:09 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Intradermal, Fractional Dose of HPV Vaccines:

NCT04235257
View directory record Official record
Conditions
HPV Infection, HPV Vaccine
Interventions
HPV vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
27 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 20, 2026, 7:09 PM EDT
Not listed Phase 2 Interventional

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

NCT04253912
View directory record Official record
Conditions
Warts
Interventions
VBP-245, Placebo Gel (no Povidone-Iodine)
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hunt Valley, Maryland • Plymouth Meeting, Pennsylvania • Sugarloaf, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Jul 20, 2026, 7:09 PM EDT
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 20, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

NCT02715752
View directory record Official record
Conditions
Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection, Cytomegalovirus Infections
Interventions
Gene-Eden-VIR/Novirin
Dietary Supplement
Lead sponsor
The Center for the Biology of Chronic Disease
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Valley Cottage, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Jul 20, 2026, 7:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

NCT05625633
View directory record Official record
Conditions
Warts
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
Biological · Other
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Jul 20, 2026, 7:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

NCT07232355
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Atila Biosystems Inc.
Industry
Eligibility
30 Years to 64 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 20, 2026, 7:09 PM EDT